Cours suspendu

Communiqués FUSN PHAR

Actions

FUSN

CA36118A1003

Temps Différé Nasdaq 22:00:00 03/06/2024			Varia. 5j.	Varia. 1 janv.
21,55 ^USD	+0,14%		-.--%	-

04/06/24	Fusion Pharmaceuticals déclare que l'acquisition de 2,4 milliards de dollars par une unité d'AstraZeneca est terminée	MT
04/06/24	AstraZeneca AB a finalisé l'acquisition de Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) auprès d'un groupe d'actionnaires.	CI

Communiqués

04/06/24	Acquisition of Fusion Pharmaceuticals Completed	PR
31/05/24	Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement	AQ
31/05/24	Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement	PR
29/05/24	Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca	PR
09/05/24	Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer	PR
09/05/24	FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN	BU
07/05/24	Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates	AQ
25/04/24	Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order	AQ
25/04/24	Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order	PR
09/04/24	Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024	AQ
20/03/24	Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates	AQ
20/03/24	FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN	BU
19/03/24	AstraZeneca to buy Canadian cancer treatment developer Fusion Pharmaceuticals	AQ
19/03/24	Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer	PR
07/03/24	Fusion Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ
06/03/24	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
05/03/24	Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting	AQ
26/02/24	Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences	PR
16/02/24	Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy	PR
07/02/24	Fusion Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	PR
06/02/24	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
04/01/24	Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates	PR
08/11/23	Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
08/11/23	Fusion Pharmaceuticals to Present at Upcoming Investor Conferences	PR
07/11/23	Fusion Pharmaceuticals Announces Third Quarter 2023 Financial Results and Clinical Program Updates	AQ